

WOAH Reference Laboratory Reports Activities 2022

Activities in 2022

This report has been submitted : 24 avril 2023 17:31

Laboratory Information

Name of disease (or topic) for which you are a designated WOA Reference Laboratory:	African horse sickness
Address of laboratory:	The Pirbright Institute, Ash Road, Pirbright, Woking, Surrey, UK, GU24 0NF
Tel.:	+441483231344
E-mail address:	carrie.batten@pirbright.ac.uk
Website:	https://www.pirbright.ac.uk/our-science/vector-borne-viral-diseases/non-vesicular-disease-reference-laboratory
Name (including Title) of Head of Laboratory (Responsible Official):	Prof Bryan Charleston, Institute Director
Name (including Title and Position) of WOA Reference Expert:	Dr Carrie Batten, Head of the non vesicular reference laboratories
Which of the following defines your laboratory? Check all that apply:	Research Institute

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOA Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
ELISA	Yes	506	0
Direct diagnostic tests		Nationally	Internationally

Real-time RT-PCR	Yes	0	83
Virus Isolation	Yes	0	1

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?H?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA?H Members?

Yes

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOA?H MEMBER COUNTRIES	COUNTRY OF RECIPIENTS
AHS9 nucleic acid	PCR	Provide	0	100ul	1	Asia and Pacific
AHS1, 3 and 4 antiserum	ELISA/SNT	Provide	0	3 x 1ml	1	Asia and Pacific
AHS1, 2, 3, 4, 5, 6, 7, 8 and 9 antiserum	ELISA/SNT	Provide	0	9 x 2ml	1	Europe
AHS1 and 9 nucleic acid	PCR	Provide	0	2 x 200ul	1	America

4. Did your laboratory produce vaccines?

Not applicable

5. Did your laboratory supply vaccines to WOA?H Members?

Not applicable

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOA?H Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOA?H Standards for the designated pathogen or disease?

No

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOA?H Members?

Yes

				NO. SAMPLES RECEIVED
--	--	--	--	----------------------

NAME OF WOAHP MEMBER COUNTRY SEEKING ASSISTANCE	DATE	WHICH DIAGNOSTIC TEST USED	NO. SAMPLES RECEIVED FOR PROVISION OF DIAGNOSTIC SUPPORT	FOR PROVISION OF CONFIRMATORY DIAGNOSES
KENYA	2022-06-06	Real-time RT-PCR and VI	0	1

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAHP Member?

Yes

NAME OF THE WOAHP MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY	PURPOSE	HOW THE ADVICE WAS PROVIDED
KENYA	Diagnostic tests	Email
SUDAN	Surveillance and testing methods	Email
	Availability of diagnostic testing labs	Email
MAURITIUS	Discuss weak positive PCR results	Email

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAHP Members other than the own?

No

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

As part of an ongoing orbivirus project we have been sequencing AHSV strains (including the recent Kenyan submission) which will be added to relevant databases once analysed

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

see below

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

0

b) International conferences:

1

Developing an xMAP multiplex assay for the rapid and simultaneous detection of AHSV serotypes 1-9: 14th Epizone annual meeting (May 2022), Barcelona

c) National conferences:

1

Developing an xMAP multiplex assay for the rapid and simultaneous detection of AHSV serotypes 1-9
The Microbiology Society Annual Conference 2022, Belfast 4 April– 7 April

d) Other (Provide website address or link to appropriate information):

0

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA H Members?

No

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO/IEC 17025:2017		Pirbright UKAS testing Schedule 2022.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Real-time RT-PCR (Agüero et al)	UKAS
Real-time RT-PCR (Guthrie et al)	UKAS
ELISA	UKAS

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

The institute works to reduce biorisk across all areas of its work

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA?

No

TOR10: NETWORK WITH WOA REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOA Reference Laboratories designated for the same pathogen or disease?

No

24. Are you a member of a network of WOA Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOA Reference Laboratories designated for the same pathogen?

Yes

PURPOSE OF THE PROFICIENCY TESTS: 1	ROLE OF YOUR REFERENCE LABORATORY (ORGANISER/ PARTICIPANT)	NO. PARTICIPANTS	PARTICIPATING WOA REF. LABS/ ORGANISING WOA REF. LAB.
Harmonisation of diagnostic tests for AHSV	Participant	44	Organiser- Spain, Participant OVI South Africa

26. Did your laboratory collaborate with other WOA Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOA Reference Laboratories for the same pathogen?

Yes

Purpose for inter-laboratory test comparisons ¹	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Region(s) of participating WOA Member Countries
Harmonisation of diagnostic tests for AHSV	Participant	44	Africa America Asia and Pacific Europe MiddleEast

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOA?

No

29. Additional comments regarding your report:

Yes

There has been little AHSV activity outside of Africa this year, hence the low level of diagnostic submissions. We continue to take enquiries for reagents, which we supply as soon as all import permits etc are in place. Additionally the Pirbright Institute holds a large collection of AHSV isolates which it makes available on request.

Dr Batten has continued to interact with the Biological standards commission via email regarding the export of horses from South Africa via Mauritius.

The Pirbright has active orbivirus and entomological research groups, who regularly publish in high impact journals, this information is directly relevant to aspects of AHSV control.

The 2022 PT was provided in December 2022 and therefore results/reports will be communicated to Pirbright in 2023.